CIK 0001815776
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
LENZ Therapeutics, Inc.
Sign in to watch- Ticker
- LENZ
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 844867570
- Phone
- +1 858-925-7000
- Business address
- 201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH, CA, 92075
- Former names
- Graphite Bio, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $9,134,778
- in 1 filing
Net −$9,134,778. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-07-19 | Jerel Davis Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2022-06-21 | Jerel Davis Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2021-06-29 | Jerel Davis Director | Conversion | +12,343,727 | 14,708,398 | ||
| 2021-06-29 | Jerel Davis Director | Conversion | +1,527,719 | 1,527,719 | ||
| 2021-06-29 | Jerel Davis Director | Purchase | +180,000 | $17.00 | $3.1M | 1,707,719 |
| 2021-06-29 | Jerel Davis Director | Conversion · Series A Preferred Stock | −30,019,945 | 0 | ||
| 2021-06-29 | Jerel Davis Director | Conversion · Series B Preferred Stock | −3,715,415 | 0 | ||
| 2021-06-24 | Jerel Davis Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2021-03-11 | Jerel Davis Director | Grant or award · Series B Preferred Stock | +3,715,415 | $5.06 | $18.8M | 3,715,415 |
| 2021-02-16 | Jerel Davis Director | Grant or award · Series A Preferred Stock | +10,000,000 | $1.00 | $10.0M | 30,019,945 |
Page 1 of 1 · 10 trades